NCT01688830View on ClinicalTrials.gov

Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 Administered Alone or With Dabigatran Etexilate

PHASE1CompletedINTERVENTIONAL
Enrollment

157

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Healthy
Interventions
DRUG

Dabigatran

DRUG

BI 655075

DRUG

Placebo

Trial Locations (1)

Unknown

1321.1.1 Boehringer Ingelheim Investigational Site, Antwerp

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT01688830 - Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 Administered Alone or With Dabigatran Etexilate | Biotech Hunter | Biotech Hunter